Q-omics provides the consensus-scored SYF2P2 profile across patient tissues and cancer cell-line models. SYF2P2 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, SYF2P2 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, SYF2P2 RNA expression shows 7,917 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, KIRC, and THYM as cancer lineages where SYF2P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYF2P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYF2P2 survival associations across molecular data types. SYF2P2 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYF2P2 RNA expression–survival associations across cancer types. High SYF2P2 expression shows unfavorable associations in COAD, LUSC, LGG, LUAD and THCA, but favorable associations in READ. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify COAD as the clearest survival context for SYF2P2 RNA expression.
This table summarizes SYF2P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SYF2P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYF2P2 shows lower tumor expression in LUSC, BRCA and THCA and higher tumor expression in KIRC. The KIRC box plot shows higher SYF2P2 RNA expression in tumor versus normal tissue (log2 FC = +0.080, t-test p < 0.001).
This table shows molecular features associated with SYF2P2 in patient tissues and cancer cell lines. In patient samples, SYF2P2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
